Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in Metastatic Neuroendocrine Tumors
NCT01169649Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in Neuroendocrine Neoplasm (NEN), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2010; status: completed.
02
Drugs
MK-2206
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT01169649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01169649.